Panc 02.13Homo sapiens (Human)Cancer cell line

Also known as: PL-1, PL1, PANC0213, Panc2.13, PANC-02-13, Panc-02.13, Panc 2.13

🤖 AI SummaryBased on 4 publications

Quick Overview

Pancreatic cancer cell line with known chromosomal abnormalities and genetic markers.

Detailed Summary

Panc 02.13 is a pancreatic cancer cell line derived from human tissue, characterized by significant chromosomal complexity and frequent genomic alterations. It is widely used in research to study the molecular mechanisms of pancreatic cancer, including chromosomal gains and losses, and has been analyzed using techniques such as comparative genomic hybridization (CGH) and spectral karyotyping (SKY). The cell line is part of a panel of 15 pancreatic cancer cell lines that have been extensively studied for their genetic profiles, providing insights into the genetic instability and heterogeneity of pancreatic tumors. Research on Panc 02.13 has contributed to understanding the role of specific chromosomal regions, such as 18q, in the progression of pancreatic cancer. The cell line's genetic characteristics make it a valuable tool for investigating the molecular basis of cancer development and for testing potential therapeutic strategies.

Research Applications

Molecular cytogenetic analysis of pancreatic cancerGenomic alterations and chromosomal instability studiesInvestigation of chromosomal regions associated with cancer progression

Key Characteristics

Significant chromosomal complexityFrequent genomic gains and lossesAnalysis using CGH and SKY techniques

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1634
Species	Homo sapiens (Human)
Tissue Source	Pancreas[UBERON:UBERON_0001264]

Donor Information

Age	64
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000031_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273Cys (c.817C>T)	Homozygous	-	PubMed=35933914
MutationSimple	KRAS	p.Gln61Arg (c.182A>G)	Unspecified	-	PubMed=27004849

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

8,11

D16S539

9,12

D18S51

D19S433

13.2,14

D21S11

D2S1338

D3S1358

16,18

D5S818

D7S820

7,11

D8S1179

12,13

FGA

21,23

Penta D

Penta E

8,13

TH01

6,9.3

TPOX

vWA

16,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.

Ried T., Schrock E., Perlman E.J., Jaffee E.M.

Cytogenet. Genome Res. 118:148-156(2007).

DOI PubMed

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Kern S.E.

Cancer Res. 66:7920-7928(2006).

DOI PubMed

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Kern S.E., Goggins M.G., Hruban R.H.

Cancer Res. 63:8614-8622(2003).

PubMed

Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Thomas M., Greten T.F., Hruban R.H., Yeo C.J., Griffin C.A.

Cancer J. Sci. Am. 4:194-203(1998).

PubMed